Hexarelin

1. Quick Facts

Property	Value
Category	Growth Hormone Secretagogue
Risk Level	Moderate/High
Research Status	Moderate Human Research / Extensive Preclinical Research
Administration	Subcutaneous Injection
Typical Frequency	1–3 Times Daily
Estimated Half-Life	Short Plasma Half-Life
Primary Research Interest	Growth Hormone Release / Recovery / Cardiovascular Research

Important Disclaimer

This material is provided strictly for educational and informational purposes related to peptide research and growth hormone signaling compounds. Hexarelin is a biologically active growth hormone secretagogue capable of significantly altering growth hormone, cortisol, prolactin, and metabolic signaling pathways. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.

2. Summary

Hexarelin is a synthetic growth hormone secretagogue belonging to the GHRP (Growth Hormone Releasing Peptide) family. It is generally regarded as one of the most potent compounds within this class and has been extensively studied for its ability to stimulate pulsatile growth hormone release.

Unlike many other GHRPs, Hexarelin has also attracted research interest for potential cardiovascular effects, including myocardial protection, cardiac remodeling, and vascular function. Research interest commonly centers around growth hormone signaling, recovery pathways, endocrine function, and cardioprotective mechanisms.

What People Commonly Claim

Produces stronger HGH release than other GHRPs
Improves recovery and tissue repair
Enhances body composition
Supports muscle growth
Provides cardiovascular protection
Produces less hunger than GHRP-6
Improves athletic performance

What the Literature Actually Shows

Hexarelin reliably stimulates growth hormone release.
The compound activates ghrelin receptors and growth hormone secretagogue pathways.
Evidence for growth hormone release is strong.
Evidence for cardiovascular effects is promising but remains largely preclinical.
Hexarelin may influence cortisol and prolactin signaling.
Receptor desensitization may occur more rapidly than with some other secretagogues.
Long-term human outcome data remain limited.

CKF Transparency Note: Hexarelin is one of the most potent growth hormone secretagogues studied within the GHRP class and reliably stimulates growth hormone release. Unlike GHRP-2 and GHRP-6, Hexarelin has also been investigated for potential cardiovascular effects, including cardiac protection and myocardial function. However, much of this research remains preclinical, and long-term human outcome data are limited. Readers should distinguish between established growth hormone-releasing effects and broader claims regarding performance enhancement, body composition, or cardiovascular benefits that remain under investigation.

3. Reconstitution Guide

Vial Size: 10 mg
Dilutant Type: BAC Water
Amount of Dilutant Added: 3 mL
Final Concentration: 3.33 mg/mL

At this concentration:
• 100 mcg = 0.030 mL (3.0 units)
• 300 mcg = 0.090 mL (9.0 units)

*Different vial sizes may limit reconstitution volume. If your product differs from the specifications listed here, please use the Peptide Calculator to calculate custom concentrations and dosing protocols.

4. Route of Administration

Hexarelin is most commonly administered as a subcutaneous injectable growth hormone secretagogue.

Primary Route: SubQ Injection
Preferred Timing: Commonly administered in fasted states
Administration Notes: Frequently researched in conjunction with GHRH analogs and recovery-focused protocols.

5. Typical Research Protocols

Product Strength: 3.33 mg/mL
Typical Delivered Amount: 100–300 mcg per dose
Frequency: 1–3 times daily
Cycle Length: 4–8 weeks on / 2–4 weeks off
Special Notes: Hexarelin is commonly discussed as one of the most potent GHRP-class secretagogues. Researchers frequently emphasize shorter cycle lengths and periodic breaks because receptor desensitization may occur more rapidly than with some other secretagogues. Compared with GHRP-6, Hexarelin is generally associated with less appetite stimulation while maintaining strong growth hormone release signaling.

6. Mechanism of Action

Hexarelin functions by activating growth hormone secretagogue receptors (GHS-R1a), stimulating pulsatile growth hormone release and downstream endocrine signaling pathways.

Growth hormone release signaling
Ghrelin receptor activation
Potential IGF-1 enhancement
Recovery signaling support
Metabolic pathway modulation
Potential cardiovascular signaling effects

The compound is frequently studied alongside GHRH analogs because of the complementary mechanisms involved in growth hormone release.

7. Potential Benefits

Potential increase in growth hormone signaling
Enhanced recovery support
Possible sleep-quality improvements
Potential body composition support
Possible connective tissue recovery support
Potential synergistic effects with GHRH analogs
Potential cardiovascular-support signaling

8. Potential Risks / Side Effects

Moderate/High

Water retention
Elevated cortisol signaling
Elevated prolactin signaling
Numbness or tingling
Fatigue
Potential insulin sensitivity changes
Possible receptor desensitization with prolonged use

9. Half-Life

Hexarelin is generally considered a short-acting growth hormone secretagogue with a relatively short circulating plasma half-life.

However, downstream growth hormone, IGF-1, and endocrine signaling effects may persist substantially longer than measurable plasma concentrations.

10. Storage Information

Store refrigerated before and after reconstitution
Protect from direct light exposure
Avoid repeated freeze-thaw cycles
Maintain sterile handling practices during preparation

11. Contraindications / Warnings

Active cancer concerns
Uncontrolled diabetes
Pregnancy or breastfeeding
Known hypersensitivity to peptide compounds
Use alongside multiple hormone-modulating compounds without appropriate oversight

12. Further Study

Hexarelin possesses a larger evidence base than many growth hormone secretagogues because researchers have investigated both endocrine and cardiovascular effects. Readers should distinguish between well-established growth hormone release effects and broader claims regarding performance enhancement or cardioprotection.

Current Evidence Gaps

Long-term human safety outcomes
Performance-enhancement efficacy
Body composition outcomes
Optimal cycle lengths
Long-term cardiovascular outcomes
Comparative studies versus newer secretagogues

13. Research References

PubMed
PubMed Central (PMC)
NIH Publications
Endocrinology literature
Growth hormone secretagogue research
Cardiovascular research literature

14. Last Reviewed

June 2026